News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Amgen Shares Soar As Roche Anti-Anemia Drug CERA Delayed
February 1, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Amgen Inc. stock climbed Wednesday after Roche Holding AG of Switzerland delayed a plan to submit its anemia drug for U.S. regulatory approval, further opening the opportunity for Amgen's drug, Aranesp.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Amgen
Roche
MORE ON THIS TOPIC
Regulatory
Atara Climbs Amid Report of FDA Inconsistency Leading to Cell Therapy’s Rejection
February 26, 2026
·
1 min read
·
Tristan Manalac
Drug pricing
Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU
February 25, 2026
·
2 min read
·
Annalee Armstrong
Vaccines
Postponed ACIP Meeting Rescheduled for Mid-March
February 25, 2026
·
3 min read
·
Tristan Manalac
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
·
2 min read
·
Tristan Manalac
